HK1040493B - 哺乳動物細胞激動素合成抑制因子的製藥用途 - Google Patents

哺乳動物細胞激動素合成抑制因子的製藥用途

Info

Publication number
HK1040493B
HK1040493B HK02101932.7A HK02101932A HK1040493B HK 1040493 B HK1040493 B HK 1040493B HK 02101932 A HK02101932 A HK 02101932A HK 1040493 B HK1040493 B HK 1040493B
Authority
HK
Hong Kong
Prior art keywords
medicament
manufacturing
synthesis inhibitory
inhibitory factor
cytokine synthesis
Prior art date
Application number
HK02101932.7A
Other languages
English (en)
Other versions
HK1040493A1 (en
Inventor
蒂莫菲‧R‧莫斯曼
凱文‧W‧穆爾
馬塔‧W‧邦德
保羅‧J‧M‧比埃拉
Original Assignee
先靈公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 先靈公司 filed Critical 先靈公司
Publication of HK1040493A1 publication Critical patent/HK1040493A1/xx
Publication of HK1040493B publication Critical patent/HK1040493B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02101932.7A 1989-06-28 2002-03-13 哺乳動物細胞激動素合成抑制因子的製藥用途 HK1040493B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37266789A 1989-06-28 1989-06-28
US45395189A 1989-12-20 1989-12-20

Publications (2)

Publication Number Publication Date
HK1040493A1 HK1040493A1 (en) 2002-06-14
HK1040493B true HK1040493B (zh) 2005-12-16

Family

ID=27005854

Family Applications (3)

Application Number Title Priority Date Filing Date
HK98109520A HK1008834A1 (en) 1989-06-28 1998-07-29 Cytokine synthesis inhibitory factor and methods of using same
HK02101932.7A HK1040493B (zh) 1989-06-28 2002-03-13 哺乳動物細胞激動素合成抑制因子的製藥用途
HK02101934.5A HK1040531B (zh) 1989-06-28 2002-03-13 製備哺乳動物細胞激動素合成抑制因子的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK98109520A HK1008834A1 (en) 1989-06-28 1998-07-29 Cytokine synthesis inhibitory factor and methods of using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK02101934.5A HK1040531B (zh) 1989-06-28 2002-03-13 製備哺乳動物細胞激動素合成抑制因子的方法

Country Status (22)

Country Link
EP (2) EP0405980A1 (zh)
JP (1) JP2813063B2 (zh)
KR (1) KR0183035B1 (zh)
CN (3) CN1051393A (zh)
AT (1) ATE180833T1 (zh)
AU (1) AU635058B2 (zh)
CA (1) CA2062763C (zh)
CS (1) CS414591A3 (zh)
DE (1) DE69033143T2 (zh)
DK (1) DK0567450T3 (zh)
ES (1) ES2132068T3 (zh)
FI (1) FI107926B (zh)
GR (1) GR3030404T3 (zh)
HK (3) HK1008834A1 (zh)
HU (1) HU216310B (zh)
IL (1) IL94878A (zh)
NO (1) NO301718B1 (zh)
NZ (1) NZ234291A (zh)
PT (1) PT94514B (zh)
SG (1) SG52282A1 (zh)
TW (1) TW218383B (zh)
WO (1) WO1991000349A1 (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827513A (en) * 1990-06-29 1998-10-27 Schering Corporation Methods of treating insulin-dependent diabetes mellitus by administration of IL-10
CZ282523B6 (cs) * 1991-01-16 1997-07-16 Schering Corporation Iterleukin - 10 pro léčení nádorů, farmaceutický prostředek jej obsahující, jeho použití a způsob výroby
WO1992012726A1 (en) * 1991-01-16 1992-08-06 Schering Corporation Use of interleukin-10 in adoptive immunotherapy of cancer
US6106823A (en) 1991-01-16 2000-08-22 Schering Corporation Treatment of neoplastic disease with interleukin-10
DE4122402A1 (de) * 1991-07-04 1993-01-07 Schering Ag Verwendung von interleukin 10 zur herstellung von arzneimitteln mit tumorhemmender wirksamkeit
DK0600970T3 (da) * 1991-08-06 2000-05-29 Schering Corp Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
US5833976A (en) * 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
US6884410B1 (en) 1992-03-04 2005-04-26 Schering Corporation Methods for modulating antigen-specific immune responses
US6277635B1 (en) 1992-03-04 2001-08-21 Schering Corporation Use of interleukin-10 to produce a population of suppressor cells
KR950700079A (ko) * 1992-03-04 1995-01-16 에릭 에스. 딕커 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
DK0671933T3 (da) * 1992-08-20 1998-09-23 Schering Corp Hidtil ukendte anvendelser af IL-10
US5601815A (en) * 1992-08-21 1997-02-11 Schering Corp IL-4 and IL-10 to downregulate delayed-type hypersensitivity and cytokine expresion by T-cells
JPH08501549A (ja) * 1992-09-18 1996-02-20 スケアリング コーポレイション Ｈｉｖ感染された患者におけるｔヘルパー細胞の免疫担当能力の回復
ES2131122T3 (es) * 1992-10-01 1999-07-16 Schering Corp Uso de il-10 para prevenir la diabetes mellitus dependiente de insulina.
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
JPH08510719A (ja) * 1993-02-01 1996-11-12 ユニヴェルシテ リブル ドゥ ブリュッセル アンスティテュション ダンセニュマン ユニヴェルシテル 有効量のインターロイキン−１０、その類似体および／または作動薬を含有する医薬組成物の使用
US5328989A (en) * 1993-03-05 1994-07-12 Schering-Plough Purification of human interleukin-10 from a cell culture medium
US5449688A (en) * 1993-03-30 1995-09-12 The United States Of America As Represented By The Department Of Health And Human Services Method of treating chronic inflammatory diseases
SG43798A1 (en) * 1993-07-26 1997-11-14 Schering Corp Agonists and antagonistis of human interleukin-10
US5650060A (en) * 1994-01-28 1997-07-22 Minnesota Mining And Manufacturing Company Ionically conductive agent, system for cathodic protection of galvanically active metals, and method and apparatus for using same
CZ1497A3 (en) * 1994-07-05 1997-05-14 Steeno Res Group As Polypeptide, its use and pharmaceutical composition based thereon, a nucleotide sequence and antibody
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
CN100389126C (zh) * 1995-12-13 2008-05-21 儿童医学中心公司 内皮细胞增殖抑制剂及其应用方法
AU4385696A (en) * 1996-01-18 1997-08-11 Christian Gronhoj Larsen Synthetic il-10 analogues
CN1216470A (zh) * 1996-04-17 1999-05-12 帕特里克·T·普伦德加斯特 脱氢表雄酮组合治疗方法
JP2001500125A (ja) * 1996-09-06 2001-01-09 シェーリング コーポレイション コレステロールレベルを低下させるための方法
AU5221998A (en) * 1997-04-17 1998-11-13 Patrick T. Prendergast Combination therapy utilising 17-ketosteroids and interleukin inhibitors, or interleukin-10 potionally with interleukin inhibitors
US6465176B1 (en) * 1998-10-02 2002-10-15 Message Pharmaceuticals, Inc. Method for identifying compounds RNA/RNA binding protein interactions
AU5047600A (en) * 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
EP1283722A1 (en) 2000-03-31 2003-02-19 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
EP2582386A2 (en) 2010-06-16 2013-04-24 Allergan, Inc. Il-10 and methods of treating ocular and other diseases
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
JP2020508436A (ja) 2016-12-07 2020-03-19 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
WO2018183931A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202003428D0 (en) * 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
IE62650B1 (en) * 1989-08-04 1995-02-22 David & Sons Ltd Dispensing apparatus
CA2071907C (en) * 1989-12-20 2000-08-08 Kevin W. Moore Bcrf1 proteins as inhibitors of interferon-y

Also Published As

Publication number Publication date
CN1198642C (zh) 2005-04-27
DE69033143T2 (de) 1999-10-21
KR920701437A (ko) 1992-08-11
HU216310B (hu) 1999-06-28
DK0567450T3 (da) 1999-12-13
ES2132068T3 (es) 1999-08-16
NO915115D0 (no) 1991-12-27
KR0183035B1 (ko) 1999-04-01
NO915115L (no) 1992-02-26
EP0567450B1 (en) 1999-06-02
CA2062763C (en) 2010-01-05
GR3030404T3 (en) 1999-09-30
FI107926B (fi) 2001-10-31
HK1008834A1 (en) 1999-05-21
CN1317569A (zh) 2001-10-17
IL94878A0 (en) 1991-04-15
NO301718B1 (no) 1997-12-01
ATE180833T1 (de) 1999-06-15
CN1318589C (zh) 2007-05-30
JPH04502560A (ja) 1992-05-14
CN1051393A (zh) 1991-05-15
EP0405980A1 (en) 1991-01-02
HUT61048A (en) 1992-11-30
TW218383B (zh) 1994-01-01
EP0567450A1 (en) 1993-11-03
IL94878A (en) 2003-01-12
CA2062763A1 (en) 1990-12-29
HU906705D0 (en) 1992-03-30
AU6077090A (en) 1991-01-17
SG52282A1 (en) 1998-09-28
DE69033143D1 (de) 1999-07-08
CN1317343A (zh) 2001-10-17
WO1991000349A1 (en) 1991-01-10
HK1040531A1 (en) 2002-06-14
PT94514A (pt) 1991-04-18
JP2813063B2 (ja) 1998-10-22
CS414591A3 (en) 1992-12-16
AU635058B2 (en) 1993-03-11
PT94514B (pt) 1998-02-27
HK1040493A1 (en) 2002-06-14
HK1040531B (zh) 2008-01-11
FI916126A0 (fi) 1991-12-27
NZ234291A (en) 1992-11-25

Similar Documents

Publication Publication Date Title
HK1040493A1 (en) Use of mammalian cytokine synthesis inhibitory factor in manufacturing a medicament.
CA2069428A1 (en) A mammalian cytokine, il-11
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
CA2193993A1 (en) New hil-4 mutant proteins used as antagonists or partial agonists of human interleukin 4
JPS6470473A (en) Novel imidazolidine substituted with hydroxymethyl group and substituted phenyl group, manufacture, use as drug, pharmaceutical composition and intermediate
IT1206730B (it) Amidi ed esteri di diidropiridinildicarbossilato farmaceuticamente utili.
NO922456L (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
IT8867088A0 (it) Dispositivo di regolazione d altezza particolarmente per sedie tavoli e simili
ATE111357T1 (de) Synergetische immunostimulierende zusammensetzung und ihre verwendung.
ATA264487A (de) Homogene, rekombinante immun-interferonfragmente
TW372873B (en) A novel anti-neoplastic cytokine
IT8648751A0 (it) 1-n-propil-3-(2-metil-butil)-7-(5idrossiesil)-8-alchil-xantine ad attivita' antibroncospastica,composizioni farmaceutiche che le contengono e relativo procedimento per laloro preparazione

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20100626